XOSPATA® - for Acute Myeloid Leukemia
XOSPATA® (Gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 mutation
Select patients for the treatment of AML with XOSPATA® based on the presence of FLT3 mutations in the blood or bone marrow. Monitor patients closely for symptoms of Posterior Reversible Encephalopathy Syndrome (PRES), QTc interval prolongation, anemia, electrolyte abnormalities and pancreatitis. Treatment continued until disease progression or unacceptable toxicity. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
XOSPATA® (Gilteritinib) PO 120 mg Daily N/A N/A N/A N/A